Literature DB >> 17233545

Management of gout in older adults: barriers to optimal control.

Karl T Hoskison1, Robert L Wortmann.   

Abstract

Gout, a common inflammatory arthritis, can be diagnosed with absolute certainty. Gout results from the body's reaction to urate crystals deposited in tissues, and this pathophysiology is well understood. If used appropriately, available therapies can be entirely effective in not only treating the symptoms of gout, but also in eliminating the excess urate from the body, thereby eradicating the disease. Because of these facts, management of patients with gout should be successful. However, management of gout is particularly challenging in the elderly, even though the principles of management are the same for all age groups. The purpose of this article is to review these principles and discuss them as they pertain to the elderly. The classic gout attack is acute in onset, extremely painful and associated with marked swelling, warmth, erythema and tenderness of a single joint. However, the diagnosis of gout may be challenging in the elderly because atypical presentations are more common in this group. Treatment of acute gout involves the use of NSAIDs, colchicine, corticosteroids or corticotropin (adrenocorticotropic hormone). Unfortunately, co-morbid conditions such as chronic kidney disease, peptic ulcer disease and congestive heart failure may make the use of these agents dangerous or contraindicated. Thus, it is important to try to treat an acute flare of gout at the earliest sign, because the sooner treatment is initiated, the faster the inflammation will resolve. Urate-lowering agents include allopurinol and uricosuric agents. These also must be used judiciously in the elderly. However, if used at the lowest dose that maintains the serum urate level below 5.0-6.0 mg/dL, the excess urate in the body will be eliminated, acute flares will no longer occur and tophi will resolve. Gout is often seen in association with hypertension, excessive alcohol consumption, obesity and hypertriglyceridaemia. These conditions and the medications used to treat them may contribute to the hyperuricaemia. Treating these conditions and using medications that do not promote hyperuricaemia will aid in the management of gout. Despite the challenges that often complicate the management of gout in the elderly, an understanding of the pathophysiology of the disease and both the indications and limitations of the medications used should allow successful treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17233545     DOI: 10.2165/00002512-200724010-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  99 in total

Review 1.  How well have diagnostic tests and therapies for gout been evaluated?

Authors:  N Schlesinger; D G Baker; H R Schumacher
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

2.  An unusual systemic presentation of gout.

Authors:  S Kini; G Mittal; C Balakrishna; G Mangat; A V Hegde; V R Joshi
Journal:  J Assoc Physicians India       Date:  2000-03

3.  Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.

Authors:  Alexander Tenenbaum; Enrique Z Fisman; Valentina Boyko; Michal Benderly; David Tanne; Moti Haim; Zipora Matas; Michael Motro; Solomon Behar
Journal:  Arch Intern Med       Date:  2006-04-10

4.  Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies.

Authors:  C A Iacobuzio-Donahue; E L Lee; S C Abraham; J H Yardley; T T Wu
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

5.  Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

Authors:  M F van Lieshout-Zuidema; F C Breedveld
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

6.  Colchicine induced neuromyopathy in a patient with normal renal function.

Authors:  N A Pirzada; M Medell; I I Ali
Journal:  J Clin Rheumatol       Date:  2001-12       Impact factor: 3.517

7.  Alcohol use, comorbidity, and mortality.

Authors:  Alison A Moore; Lisa Giuli; Robert Gould; Peifeng Hu; Kefei Zhou; David Reuben; Gail Greendale; Arun Karlamangla
Journal:  J Am Geriatr Soc       Date:  2006-05       Impact factor: 5.562

8.  Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; K G Saag
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

9.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

10.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.

Authors:  Nancy J Ganson; Susan J Kelly; Edna Scarlett; John S Sundy; Michael S Hershfield
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  11 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 2.  Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

Authors:  S Schlee; L C Bollheimer; T Bertsch; C C Sieber; P Härle
Journal:  Z Gerontol Geriatr       Date:  2017-02-28       Impact factor: 1.281

Review 3.  Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.

Authors:  S Schlee; L C Bollheimer; T Bertsch; C C Sieber; P Härle
Journal:  Z Gerontol Geriatr       Date:  2017-02-23       Impact factor: 1.281

Review 4.  Management of hyperuricemia in gout: focus on febuxostat.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

Review 5.  Febuxostat.

Authors:  Philip I Hair; Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Authors:  Nazia Rashid; Gerald D Levy; Yi-Lin Wu; Chengyi Zheng; River Koblick; T Craig Cheetham
Journal:  Rheumatol Int       Date:  2015-05-20       Impact factor: 2.631

7.  Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.

Authors:  Zhijun Xie; Huaxiang Wu; Xiaoqing Jing; Xiuyang Li; Yasong Li; Yongmei Han; Xiangfu Gao; Xiaopo Tang; Jing Sun; Yongshen Fan; Chengping Wen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Case Report: Articular Gout in Four Dogs and One Cat.

Authors:  Hyo-Sung Kim; Hyun-Jeong Hwang; Han-Jun Kim; Sun Hee Do
Journal:  Front Vet Sci       Date:  2022-04-26

9.  Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Authors:  Robert A Terkeltaub; H Ralph Schumacher; John D Carter; Herbert S B Baraf; Robert R Evans; Jian Wang; Shirletta King-Davis; Steven P Weinstein
Journal:  Arthritis Res Ther       Date:  2013-02-01       Impact factor: 5.156

10.  Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study.

Authors:  Lian-Yun Li; Jia-Xiang Ni
Journal:  Exp Ther Med       Date:  2014-09-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.